human
coronavirus
appear
end
led
pandem
high
morbid
mortal
current
effect
drug
target
viru
drug
repurpos
repres
shortterm
strategi
treat
million
infect
patient
low
cost
hydroxychloroquin
show
antivir
effect
vitro
vivo
show
efficaci
especi
combin
azithromycin
preliminari
clinic
trial
demonstr
combin
hydroxychloroquin
azithromycin
synergist
effect
vitro
concentr
compat
obtain
human
lung
sinc
end
world
encount
pandem
condit
attribut
novel
coronaviru
sarscov
coronaviru
identifi
infect
human
popul
first
one
pandem
potenti
nonimmun
popul
centuri
find
therapeut
thu
crucial
propos
repurpos
exist
drug
strategi
present
advantag
safeti
profil
drug
known
could
easili
produc
rel
low
cost
thu
quicker
deploy
new
drug
vaccin
chloroquin
decadesold
antimalari
agent
analog
quinin
known
inhibit
acidif
intracellular
compart
shown
vitro
vivo
mice
model
activ
differ
subtyp
coronavirus
merscov
test
vitro
sarscov
caus
reduct
viral
replic
day
moreov
test
vitro
shown
inhibit
viral
replic
sarscov
detect
pcr
assay
hydroxychloroquin
hydroxychloroquin
sulfat
nethylnbhydroxyethylamino
quinolin
sulfat
shown
activ
vitro
exhibit
less
toxic
profil
drug
well
known
current
use
mostli
treat
autoimmun
diseas
also
team
treat
q
fever
diseas
whippl
diseas
clinic
context
concentr
obtain
serum
close
dose
mg
per
day
sever
month
clinic
test
chloroquin
hydroxychloroquin
treat
underway
china
trial
use
hydroxychloroquin
progress
us
clinicaltrialsgov
identifi
europ
discoveri
trial
drug
repurpos
effort
antibacteri
compon
also
test
teicoplanin
glycopeptid
demonstr
vitro
inhibit
cellular
penetr
ebola
viru
sarscov
azithromycin
azithromycin
dihydr
macrolid
shown
antivir
activ
zika
azithromycin
wellknown
safe
drug
wide
prescrib
us
exampl
million
treatment
cours
children
year
age
alon
recent
studi
identifi
two
compound
azithromycin
hydroxychloroquin
among
total
potenti
activ
agent
possibl
treatment
diseas
preliminari
clinic
studi
hydroxychloroquin
even
greater
potenc
combin
hydroxychloroquin
azithromycin
found
effect
reduc
viral
load
patient
sinc
begin
epidem
marseil
region
isol
numer
strain
test
one
use
differ
concentr
hydroxychloroquin
azithromycin
combin
vero
cell
procedur
viral
isol
sarscov
strain
detail
elsewher
viral
product
done
cm
cell
cultur
flask
contain
vero
cell
american
type
cultur
collect
minimum
essenti
media
gibco
thermofisch
mem
fetal
bovin
serum
glutamin
cytopath
effect
monitor
daili
invert
microscop
fig
nearli
complet
cell
lysi
approxim
h
viral
supernat
use
inocul
plate
determin
strain
infecti
particl
per
ml
briefli
prepar
plate
cellsml
vero
per
well
use
mem
fetal
bovin
serum
lglutamin
plate
incub
overnight
co
atmospher
drug
concentr
test
express
micromol
per
liter
hydroxychloroquin
associ
azithromycin
test
done
least
triplic
repeat
two
time
except
condit
hydroxychloroquin
associ
azithromycin
repeat
third
time
four
hour
infect
cell
cultur
supernat
remov
replac
drug
dilut
cultur
medium
viru
suspens
cultur
medium
ad
well
except
neg
control
medium
ad
multipl
infect
moi
rtpcr
done
min
postinfect
one
plate
h
postinfect
second
plate
well
collect
ad
readyus
vxl
buffer
qiacub
kit
qiagen
germani
extract
done
use
manual
high
pure
rna
isol
kit
roch
life
scienc
follow
recommend
procedur
rtpcr
done
use
roch
realtim
pcr
readi
rna
viru
master
kit
primer
design
e
gene
use
protocol
amran
et
al
roch
instrument
ii
rel
viral
quantif
done
compar
posit
control
virus
without
drug
delta
delta
ct
method
perform
statist
analysi
use
graphpad
prism
graphpad
softwar
la
jolla
california
usa
distribut
data
follow
normal
law
non
parametr
kruskalw
test
use
compar
combin
posit
control
use
dunn
test
use
correct
multipl
comparison
test
use
p
paramet
bilater
twosid
signific
pvalu
indic
cytotox
associ
drug
combin
control
well
without
virus
detect
rna
viral
product
cyclethreshold
ct
invers
correl
rna
copi
number
posit
control
associ
cell
lyse
case
cell
lyse
h
correl
viral
product
compar
control
fig
combin
azithromycin
hydroxychloroquin
led
signific
inhibit
viral
replic
well
contain
hydroxychloroquin
combin
azithromycin
pvalu
fig
rel
viral
inhibit
respect
fig
other
condit
signific
agreement
rel
viral
rna
load
reduct
cytopath
effect
could
observ
well
h
post
infect
compar
posit
control
work
identifi
strong
synergist
effect
combin
hydroxychloroquin
azithromycin
hydroxychloroquin
demonstr
vitro
inhibit
replic
sarscov
concentr
drug
studi
base
known
cytotox
drug
cytotox
cc
effect
microorgan
inhibitori
concentr
zika
viru
azithromycin
show
activ
ic
rang
depend
moi
without
notabl
effect
ec
high
concentr
observ
efficaci
azithromycin
rna
virus
probabl
share
macrolid
clarithromycin
non
antibiot
macrolid
observ
effect
rhinoviru
vitro
vivo
sulfat
hydroxychloroquin
could
impli
modul
immun
respons
reduc
proinflammatori
cytokin
modif
lysosom
acidif
procedur
aspect
may
play
keyston
role
sever
case
sarscoronavirus
inde
mous
model
sarscov
pneumonia
lung
affect
associ
cytokin
storm
parallel
azithromycin
known
inhibit
viral
replic
zika
viru
vitro
enlarg
viral
infect
context
azithromycin
associ
upregul
interferon
iii
concern
respiratori
syncyti
viru
also
shown
macrolid
reduc
acid
lysosom
downregul
protein
sarscov
context
azithromycin
could
potenti
effect
hydroxychloroquin
similar
mechan
vero
shown
hydroxychloroquin
cc
close
significantli
concentr
test
herein
sarscov
ic
hydroxychloroquin
determin
variou
moi
respect
one
main
critic
previous
publish
data
drug
concentr
viral
inhibit
use
vitro
difficult
translat
clinic
due
side
effect
would
occur
concentr
synergi
hydroxychloroquin
azithromycin
observ
herein
concentr
achiev
vivo
detect
serum
pulmonari
tissu
respect
data
thu
agreement
clinic
efficaci
combin
hydroxychloroquin
azithromycin
observ
gautret
et
al
support
clinic
use
drug
combin
especi
earli
stage
infect
patient
develop
respiratori
distress
syndrom
associ
cytokin
storm
becom
less
treatabl
antivir
treatment
pictur
captur
zeiss
axiocam
erc
h
post
infect
magnitud
overview
monolay
well
condit
azithromycin
associ
hydroxychloroquin
neg
control
well
posit
control
well
observ
done
h
post
infect
sarscov
strain
viral
stock
product
magnitud
author
would
like
declar
didier
raoult
consult
microbiolog
hitachi
hightech
corpor
fund
sourc
role
design
conduct
studi
collect
manag
analysi
interpret
data
prepar
review
approv
manuscript
other
author
declar
conflict
interest
fig
effect
hydroxychloroquin
azithromycin
associ
sarscov
replic
delta
ct
h
post
infect
order
axi
repres
variat
delta
cyclethreshold
obtain
rtpcr
condit
point
repres
data
obtain
one
well
number
replic
indic
condit
n
n
n
n
n
n
n
n
n
n
posit
control
median
interquartil
rang
indic
condit
repres
signific
result
p
other
signific
compar
control
percentag
inhibit
compar
control
combin
hydroxychloroquin
associ
azithromycin
data
repres
mean
sd
repres
three
independ
experi
conduct
least
triplic
